Key result
Zofenopril improves clinical outcomes and survival after acute myocardial infarction via distinct cardioprotective mechanisms.
Why the study?
Does zofenopril provide superior cardioprotective, anti-ischemic, and antiatherogenic effects in patients with cardiovascular disease and acute myocardial infarction compared to other therapies?
Does zofenopril provide superior cardioprotective, anti-ischemic, and antiatherogenic effects in patients with cardiovascular disease and acute myocardial infarction compared to other therapies?
Zofenopril offers specialized cardioprotective benefits beyond standard ACE inhibitors, particularly in the early management of acute myocardial infarction.
Supports zofenopril post-MI; leaves open head-to-head RCTs versus other ACEIs.
The review discusses various aspects of angiotensin-converting enzyme (ACE) inhibitor therapy in patients with cardiovascular disease (CVD), including acute myocardial infarction (AMI). The focus is on the modern ACE inhibitor zofenopril, its specific pharmacological characteristics, and additional cardioprotective, anti-ischemic, and antiatherogenic effects. The existing evidence of clinical effectiveness of zofenopril and its potential for a wider use in clinical practice are also addressed.
No takes yet. Share an insight, caveat, or question.
М. Г. Бубнова (2013) conducted a review in Cardiovascular disease and acute myocardial infarction. Zofenopril vs. Other ACE inhibitors or standard therapy was evaluated. Zofenopril exhibits distinct cardioprotective, anti-ischemic, and antiatherogenic properties that improve clinical outcomes and survival in patients following an acute myocardial infarction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: